Metformin as anticancer agent and adjuvant in cancer combination therapy: Current progress and future prospect
Metformin, as the preferred antihyperglycemic drug for type 2 diabetes, has been found to have a significant effect in inhibiting tumor growth in recent years. However, metformin alone in cancer treatment has the disadvantages of high dose concentrations and few targeted cancer types. Increasing stu...
שמור ב:
| Principais autores: | , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Elsevier
2024-06-01
|
| סדרה: | Translational Oncology |
| נושאים: | |
| גישה מקוונת: | http://www.sciencedirect.com/science/article/pii/S193652332400072X |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|